Author profile

Re: Prescription factors contributing to new long-term opioid use in BC. Authors reply

We thank Drs McCracken, Hawley, Panagiotoglou, Lavergne, and Gomes and Ms Peterson for their thoughtful letter about our article on new long-term opioid use in BC.[1] Our understanding is that they are concerned our... Read More

Prescription factors contributing to new long-term opioid use in British Columbia between 2013 and 2017

Background Long-term opioid therapy is associated with significant side effect profiles.[1-4] The prevalence of long-term opioid therapy has been reported to be 5.4% in the United States and 17.6% in Canada.[5,6]... Read More

Opioid prescribing patterns in British Columbia from 2013 to 2017: A population-based study

Opioids are an essential component of multimodal therapy for acute and cancer pain management. Legitimate opioid prescription use in this setting is not considered to be a major contributor to chronic opioid misuse.[1,2... Read More

Taking steps to improve care and planning for patients in British Columbia with 22q11.2 deletion syndrome

Background In 1965 Dr Angelo DiGeorge first described the syndromic presentation of infants with thymic aplasia, hypoparathyroidism, and cardiac outflow tract anomalies.[1,2] DiGeorge syndrome was later grouped with... Read More